Beijing Chunlizhengda Medical Instruments Co., Ltd. Class H AI Stock Analysis
Want to see HK:1858 full AI Analyst Report?
Beijing Chunlizhengda Medical Instruments Co., Ltd. Class H (1858) AI Stock Analysis
Beijing Chunlizhengda Medical Instruments Co., Ltd. Class H
(HKEX:1858)
The score is driven primarily by strong financial quality (high margins, very low leverage, and solid current free cash flow). This is partially offset by weaker technicals (below key longer-term moving averages and negative MACD) and tempered by only moderate valuation (P/E ~18.5) despite an attractive dividend yield (~5.24%).
Beijing Chunlizhengda Medical Instruments Co., Ltd. Class H (1858) vs. iShares MSCI Hong Kong ETF (EWH)
- Market Cap
- HKD 4.46B
- Dividend Yield
- 5.42%
- Average Volume (3M)
- 610.42K
- Price to Earnings (P/E)
- 19.1
- Beta (1Y)
- 0.95
- Revenue Growth
- -9.00%
- EPS Growth
- 10.62%
- Country
- Hong Kong
- Employees
- 841
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Medical - Devices
Beijing Chunlizhengda Medical Instruments Co., Ltd. Class H Business Overview & Revenue Model
Company Description
Beijing Chunlizhengda Medical Instruments Co., Ltd. functions as a prominent entity within the orthopedic medical device industry, dedicated to the development, manufacturing, and distribution of surgical implants, instruments, and associated medical...
How the Company Makes Money
The company primarily makes money by selling orthopedic medical devices (including implants and related surgical instruments) to healthcare providers and/or medical device distributors. Revenue is generated from product sales volume and product mix (...
Beijing Chunlizhengda Medical Instruments Co., Ltd. Class H Financial Statement Overview
Summary
Strong overall fundamentals: solid profitability with high TTM margins (gross ~67%, net ~29%), exceptionally low leverage (debt-to-equity ~0.10%), and currently healthy free cash flow (TTM FCF ~312m, +25.4% vs prior). The main offset is uneven revenue and cash flow history (notably the 2024 dip and softer TTM revenue at -6.1%), which reduces near-term consistency.
Income Statement
78PositiveBalance Sheet
95Very PositiveCash Flow
70Positive| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 909.88M | 1.05B | 805.86M | 1.21B | 1.20B | 1.11B |
| Gross Profit | 575.16M | 653.40M | 516.49M | 875.89M | 913.53M | 844.03M |
| EBITDA | 282.75M | 311.67M | 169.32M | 340.65M | 366.96M | 362.75M |
| Net Income | 269.00M | 272.54M | 124.99M | 277.82M | 307.72M | 322.36M |
Balance Sheet | ||||||
| Total Assets | 3.65B | 3.66B | 3.47B | 3.65B | 3.41B | 3.00B |
| Cash, Cash Equivalents and Short-Term Investments | 2.17B | 2.22B | 1.89B | 2.10B | 1.72B | 1.74B |
| Total Debt | 2.39M | 3.28M | 866.44K | 1.75M | 1.31M | 1.23M |
| Total Liabilities | 530.11M | 674.14M | 644.39M | 770.33M | 690.07M | 530.58M |
| Stockholders Equity | 3.12B | 2.99B | 2.82B | 2.88B | 2.72B | 2.47B |
Cash Flow | ||||||
| Free Cash Flow | 312.17M | 351.97M | -51.07M | 478.47M | 16.10M | -34.62M |
| Operating Cash Flow | 354.46M | 409.57M | -1.90M | 511.71M | 41.01M | 164.79M |
| Investing Cash Flow | 99.57M | -124.01M | 55.84M | -81.56M | -762.61M | -190.35M |
| Financing Cash Flow | -145.29M | -28.75M | -183.14M | -121.33M | -59.04M | 1.07B |
Beijing Chunlizhengda Medical Instruments Co., Ltd. Class H Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:1858, the sentiment is Negative. The current price of 7.42 is above the 20-day moving average (MA) of 7.37, below the 50-day MA of 7.62, and below the 200-day MA of 10.11, indicating a neutral trend. The MACD of -0.01 indicates Negative momentum. The RSI at 47.50 is Neutral, neither overbought nor oversold. The STOCH value of 41.41 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:1858.
Beijing Chunlizhengda Medical Instruments Co., Ltd. Class H Peers Comparison
Overall Rating
HK:178977Outperform- HK:185872Outperform
HK:219066Neutral
HK:223560Neutral
HK:999645Neutral
HK:085341Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| HK:1789 | 77Outperform | HKD 5.30B | 11.92 | 13.24% | 2.48% | 16.15% | 31.89% |
| HK:1858 | 72Outperform | HKD 5.26B | 19.07 | 8.83% | 5.42% | -9.00% | 10.62% |
| HK:2190 | 66Neutral | HKD 6.54B | 16.71 | 9.76% | 1.93% | 39.30% | 109.37% |
| HK:2235 | 60Neutral | HKD 2.82B | 28.07 | 4.08% | ― | 94.80% | ― |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| HK:9996 | 45Neutral | HKD 2.62B | -16.01 | -7.65% | ― | 21.23% | 36.89% |
| HK:0853 | 41Neutral | HKD 11.65B | 31.23 | 6.07% | ― | -3.62% | ― |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| HK:1858 | Beijing Chunlizhengda Medical Instruments Co., Ltd. Class H | 7.42 | -10.97 | -59.63% | |
| HK:0853 | MicroPort Scientific Corp | 6.08 | -5.08 | -45.56% | |
| HK:9996 | Peijia Medical Ltd. | 3.98 | -1.77 | -30.75% | |
| HK:2190 | Zylox-Tonbridge Medical Technology Co., Ltd. Class H | 18.66 | -7.52 | -28.73% | |
| HK:1789 | AK Medical Holdings Ltd. | 4.76 | -1.04 | -17.93% | |
| HK:2235 | MicroTech Medical (Hangzhou) Co., Ltd. Class H | 6.77 | 0.10 | 1.50% |
Beijing Chunlizhengda Medical Instruments Co., Ltd. Class H Corporate Events
Chunli Medical Releases Unaudited Third-Quarter 2026 Results for Dual-Listed Investors
Beijing Chunlizhengda Medical Instruments Co., Ltd., a PRC-based medical devices manufacturer listed in Hong Kong and Shanghai, reports unaudited financial results under Chinese Accounting Standards for Business Enterprises. The group operates within...
Chunlizhengda Board to Review Q3 Results and Interim Dividend
Beijing Chunlizhengda Medical Instruments Co., Ltd. has scheduled a board meeting for 30 October 2026 to approve the group’s third-quarter results for the nine months ended 30 September 2026 and to authorize their publication. The board will also con...
Chunlizhengda Faces Temporary Governance Gap After Death of Key Hong Kong Officer
Beijing Chunlizhengda Medical Instruments Co., Ltd. announced the passing of Mr. Ip Pui Sum, who served for a decade as company secretary, authorised representative in Hong Kong and process agent for legal notices. The board praised his dedication an...
Beijing Chunlizhengda Reports Stable Interim Balance Sheet for First Half of 2026
Beijing Chunlizhengda Medical Instruments has reported its unaudited consolidated interim results for the six months ended 30 June 2026, prepared in accordance with PRC accounting standards and Hong Kong disclosure rules. The announcement shows the g...
Beijing Chunlizhengda Declares Interim Cash Dividend for First Half of 2026
Beijing Chunlizhengda Medical Instruments Co., Ltd. has declared an interim ordinary cash dividend of RMB 1.3 per 10 shares for the six months ended 30 June 2026, underscoring its commitment to returning capital to shareholders. Key dates and payment...
Beijing Chunlizhengda Schedules Board Meeting to Approve 2026 Interim Results
Beijing Chunlizhengda Medical Instruments Co., Ltd., a Hong Kong-listed Chinese medical device maker specializing in orthopedic instruments, has announced that its board of directors will convene on 28 August 2026. The meeting will review and approve...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 05, 2026